Last 12 months
Inside the activity.
0 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2018 Filed Apr 3, 2018 20:30 UTC |
Ratcliffe LiamDirector
|
PurchaseCommon Stock | 275,000 | $12.00 | $3,300,000.00 |
DisclosureSEC source: 0001209191-18-022971 · doc4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 897,772 F2 · ownership.nature: The shares are held directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLBA I. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Each of the Reporting Person, Ronald M. Hunt and Vijay K. Lathi (each a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Continued in Footnote 3 F3 · ownership.nature: Continued from Footnote 2: Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 of any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 20:30 UTC |
Ratcliffe LiamDirector
|
ConversionCommon Stock | 622,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-022971 · doc4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · balance_after: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · ownership.nature: The shares are held directly by New Leaf Ventures III, L.P. ("NLV III").New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. NLV Management III is the sole general partner of NLV Associates III. NLVP is the investment adviser of NLV III.Each of NLV Associates and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Each of the Members may be deemed to have shared voting and dispositive power of these securities. Continued in Footnote 5 F5 · ownership.nature: Continued from Footnote 4: Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 of any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 20:30 UTC |
Ratcliffe LiamDirector
|
ConversionCommon Stock | 622,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-022971 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · balance_after: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The shares are held directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLBA I. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Each of the Reporting Person, Ronald M. Hunt and Vijay K. Lathi (each a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Continued in Footnote 3 F3 · ownership.nature: Continued from Footnote 2: Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 of any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries B Preferred Stock · Derivative | 877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 13 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund IV LP Disclosed balance after: 0 Underlying: Common Stock · 558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries B Preferred Stock · Derivative | 73,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 12 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 46,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries B Preferred Stock · Derivative | 13,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 11 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP Disclosed balance after: 0 Underlying: Common Stock · 8,601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries A Preferred Stock · Derivative | 35,614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 10 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund IV LP Disclosed balance after: 0 Underlying: Common Stock · 22,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries A Preferred Stock · Derivative | 2,968,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 9 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 1,890,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionSeries A Preferred Stock · Derivative | 548,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · derivative · entry 8 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP Disclosed balance after: 0 Underlying: Common Stock · 349,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 7 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund IV LP Disclosed balance after: 23,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 22,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 6 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund IV LP Disclosed balance after: 22,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 46,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 5 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 1,937,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 1,890,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 4 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 1,890,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
PurchaseCommon Stock | 94,052 | $12.00 | $1,128,624.00 |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP Disclosed balance after: 452,115 Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 8,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP Disclosed balance after: 358,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:27 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 349,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-18-001774 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP Disclosed balance after: 349,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC |
FIL LtdSee Remark 1
|
ConversionSeries B Preferred Stock · Derivative | 42,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · derivative · entry 4 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,342 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC |
FIL LtdSee Remark 1
|
ConversionSeries A Preferred Stock · Derivative | 1,744,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · derivative · entry 3 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,110,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC |
FIL LtdSee Remark 1
|
ConversionCommon Stock | 27,342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · nonDerivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC |
FIL LtdSee Remark 1
|
ConversionCommon Stock | 1,110,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.